8-K: Viatris Reports Strong Q3 Results, Driven by Base Business Growth and Strategic Initiatives

Viatris announced solid third-quarter 2024 financial results, demonstrating growth in its base business and progress in debt reduction and portfolio expansion.

Summary

• Viatris reported total revenues of $3.8 billion for the third quarter of 2024, with a 3% operational growth on a divestiture-adjusted basis.
• New product revenues reached $133 million, contributing to growth across all segments.
• U.S. GAAP net earnings were $95 million, while adjusted EBITDA grew by 4% to $1.3 billion on a divestiture-adjusted basis.
• The company repaid approximately $1.9 billion of debt and expects to achieve its long-term gross leverage target of 3.0x by the end of the year.
• Viatris entered into an exclusive licensing agreement for sotagliflozin, expanding its portfolio in cardiovascular diseases.
• The company reaffirmed its 2024 full-year outlook, expecting revenue growth of approximately 2% on a divestiture-adjusted operational basis.
• U.S. GAAP total revenues for 2024 are estimated to be between $14.60 and $15.10 billion, with a midpoint of $14.85 billion, representing a full-year decrease of approximately 4%.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong operational growth and debt reduction, but tempered by significant declines in GAAP earnings and EPS. The company's strategic moves and reaffirmed guidance provide a positive outlook, but the GAAP results are concerning.

Positives

• The company demonstrated strong operational growth in its base business.
• New product launches are contributing significantly to revenue.
• Viatris is making substantial progress in debt reduction.
• The licensing agreement for sotagliflozin expands the company's innovative portfolio.
• The company is on track to meet its long-term gross leverage target.
• Viatris was named to Forbes' list of World's Best Employers 2024 for the fourth consecutive year.
• Viatris was named to Forbes list of Worlds Top Companies for Women 2024.
• The company was upgraded in the annual MSCI ESG Rating and the ISS ESG Corporate Rating.

Negatives

• U.S. GAAP net earnings decreased from $332 million to $95 million, a 71% decline.
• U.S. GAAP diluted EPS decreased from $0.27 per share to $0.08 per share, a 70% decline.
• Total revenues declined by 5% on a U.S. GAAP basis.
• U.S. GAAP total revenues for 2024 are estimated to decrease by approximately 4%.

Risks

• The company faces potential risks related to the integration of acquisitions and divestitures.
• There are uncertainties regarding the outcomes of clinical trials and new product development.
• Changes in healthcare regulations and policies could impact the company's operations.
• The company is exposed to risks associated with global operations and currency fluctuations.
• There are inherent uncertainties in financial estimates and judgments.

Future Outlook

Viatris reaffirms its 2024 full-year outlook and continues to expect 2024 full-year revenue growth of approximately 2% on a divestiture-adjusted operational basis. The company expects to achieve its long-term gross leverage target of approximately 3.0x by the end of the year and anticipates delivering $500 to $600 million in new product revenues in 2024.

Management Comments

• Scott A. Smith, chief executive officer, stated that the company is in a period of strong global execution leading to consistent base business growth and expects this momentum to continue into next year.
• Scott A. Smith also mentioned that the company is operating from a position of financial strength with a clear and focused outlook that centers on capital allocation.
• Doretta Mistras, chief financial officer, noted that the company is on pace to achieve its long-term gross leverage target of approximately 3.0x by year end.
• Doretta Mistras also stated that the company is well-positioned to deliver consistent base business growth, while simultaneously investing in the business and returning significant capital to shareholders.

Industry Context

This announcement reflects Viatris' ongoing efforts to streamline its operations, reduce debt, and focus on strategic growth areas, aligning with broader trends in the pharmaceutical industry towards portfolio optimization and financial stability. The licensing agreement for sotagliflozin highlights the company's focus on expanding its presence in the cardiovascular therapeutic area, a significant market segment.

Comparison to Industry Standards

• Viatris' adjusted EBITDA growth of 4% is a positive sign, but it is important to compare this to peers such as Teva Pharmaceuticals and Mylan (prior to the merger), which have also been focusing on cost-cutting and debt reduction.
• The debt repayment of $1.9 billion is substantial and puts Viatris on track to meet its leverage target, which is a key metric for investors in the pharmaceutical sector. Companies like Teva have also been working to reduce their debt loads.
• The new product revenue of $133 million is a positive indicator of Viatris' ability to launch and commercialize new products, which is crucial for long-term growth. This can be compared to the new product launch performance of companies like Novartis and Pfizer.
• The licensing agreement for sotagliflozin is a strategic move to expand in the cardiovascular space, which is a competitive area. Companies like AstraZeneca and Boehringer Ingelheim have also been active in this space.
• The company's focus on returning value to shareholders through dividends and share repurchases is a common practice among established pharmaceutical companies, and it is important to compare Viatris' approach to that of its peers.

Stakeholder Impact

• Shareholders will benefit from the company's focus on returning value through dividends and share repurchases.
• Employees may be positively impacted by the company's recognition as a top employer.
• Customers will have access to new and innovative products through the company's portfolio expansion.
• Creditors will benefit from the company's debt reduction efforts.

Next Steps

• Viatris will host a conference call and live webcast to review the Q3 2024 financial results.
• The company is targeting its submission of EFFEXOR (venlafaxine) to the Pharmaceuticals and Medical Devices Agency in Japan in 2025.

Key Dates

Keywords

Viatris, Financial Results, Third Quarter, Q3 2024, Debt Repayment, Sotagliflozin, New Product Revenue, Adjusted EBITDA, Pharmaceuticals, Generics, Brands, Licensing Agreement, Cardiovascular Diseases